First-in-man study of CPX-351 : a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia

収録刊行物

• J Clin Oncol.

  J Clin Oncol. 29 979-985, 2011